Menu
Request a demo

Our products

An agile launch execution platform, with full visibility across countries and functions.
A collaborative platform for teams who plan reimbursements and HTA activities.
A collaborative platform designed to manage pharmaceutical tenders across countries.
A capability management platform that unifies capabilities, resources, and assessment.
Manage your entire pipeline. Track every move. Stay ahead, from discovery to launch.

Our expertise

Launch Readiness

Market Access

Tender Management

Featured Post

3 Pharma Trends for 2024: All about market access

  • Andre Moa
  • 12 Dec 2023
  • 19 minute read

Pharma is facing a new set of launch, market access and strategic challenges as the pandemic has changed some market characteristics for good.

Read more

Latest posts

Market Access 2025: Navigating the emerging HTA and drug reimbursement challenges

Discover insights from 'Market Access 2025' on overcoming HTA and drug reimbursement challenges. Learn strategies to navigate evolving market access hurdles.

Read more

Launch Readiness 2024: A fresh look at key trends affecting pharma product launches

Revitalized US approvals and thriving innovation are positive signs for new medicines this year. However, our Launch Readiness 2024 guide shows that cost and value remain critical to launch success.

Read more

Market Access 2023: New Report on key challenges in HTA and reimbursement

As market access barriers proliferate, digitally enabled alignment is key to optimising new drug uptake.

Read more

Launch Readiness 2023: Key trends impacting pharma product launches

Our Launch Readiness 2023 report examines the prospects and challenges for new medicines entering the market in the shadow of COVID-19.

Read more

New Report: Launch Readiness 2022 - How to address key trends and challenges

With COVID-19 driving innovation and agility, 2022 promises another rich crop of pharma launches. Closer cost-benefit scrutiny demands carefully differentiated value.

Read more

8 Pharma Trends for 2022: Towards a more holistic understanding of value

Our 8 pharma trends for 2022 assess how new directions in the industry might lead to a more holistic conception of the value and benefit of drug innovation

Read more

Rethinking Launch Readiness in 2021: The New Normal in the Shadow of COVID

COVID-19 has intensified launch challenges facing new drugs. R&D pipelines and regulatory approvals continue to deliver innovation and commercial promise.

Read more

5 Pharma Trends for 2021: Disruption and Transformation in the COVID Era

The impact of COVID-19 threads through our 5 pharma trends for 2021, whether driving vaccine R&D or political change, hampering market access or accelerating digital transformation.

Read more

2020 New Drug Approvals: Review of New FDA and EMA Marketing Authorisations

Despite the threat of pandemic disruption, US and EU drug approvals for 2020 are in good health, with breakthrough innovation much in evidence.

Read more

How the coronavirus crisis could affect your new drug launch

The coronavirus is forcing pharma to think creatively about remote working in a constrained environment. Digital technology will be crucial in softening the pandemic’s multiple impacts on drug launches.

Read more

From Volume to Value: Strategising launch readiness in 2020

The pharmaceutical market in 2020 is more about product diversity, breakthrough science and new therapeutic targets than spectacular launch volumes.

Read more

5 Pharma Trends for 2020: Counting the value and cost of innovation

The pharmaceutical market in 2020 is more about product diversity, breakthrough science and new therapeutic targets than spectacular launch volumes.

Read more

Recent Posts

Most Popular Posts

Categories

Get our latest
posts in your inbox

TRiBECA Knowledge needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Notice.